
Regulatory Announcement
Publication of Final Terms
Not for release, publication or distribution, directly or indirectly, in or into the United States.
The following documents constitute the final terms in respect of the Notes dated
DISCLAIMER - INTENDED ADDRESSEES
Please note that the information contained in the Prospectus and the Final Terms may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Final Terms is not addressed. Prior to relying on the information contained in the Final Terms you must ascertain from the Prospectus, as supplemented by the Final Terms, whether or not you are part of the intended addressees of the information contained therein.
The Notes have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act") and are subject to US tax law requirements. Subject to certain exceptions, the Securities may not be offered, sold or delivered in or into the United States or to or for the account or benefit of US persons (as defined in Regulation S under the Securities Act). No public offering of the Notes is being made in the United States.
Your right to access this service is conditional upon complying with the above requirement.
UK MIFIR professionals / ECPs-only - Manufacturer target market (UK MIFIR product governance) is eligible counterparties and professional clients only (all distribution channels).
To view the Final Terms, please paste the following URLs into the address bar of your browser:
http://www.rns-pdf.londonstockexchange.com/rns/5865S_1-2025-7-25.pdf
For further information, please contact
Colin Elion
Associate Vice President
Funding, Treasury and Balance Sheet Management
Telephone Number: +1 (416) 350-9434
Email: colin.elion@td.com
This information is provided by RNS
The company news service from the
END
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the